Amedeo Smart

Free Medical Literature Service



Bladder Cancer

  Free Subscription


1 BJU Int
5 Bladder Cancer
1 Clin Genitourin Cancer
1 Clin Transl Oncol
1 Eur Urol Focus
1 Front Oncol
1 Genes (Basel)
1 Int J Mol Sci
4 J Cancer
1 J Immunother Cancer
2 J Urol
1 Nanotechnology
1 Neurourol Urodyn
1 Oncol Lett
1 Oncotarget
2 Urol Oncol
1 Urology

    BJU Int

  1. Bladder cancer: diagnosis and management of bladder cancer: (c) NICE (2015) Bladder cancer: diagnosis and management of bladder cancer.
    BJU Int. 2017;120:755-765.
    >> Share

    Bladder Cancer

  2. MILBAR N, Kates M, Chappidi MR, Pederzoli F, et al
    Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer.
    Bladder Cancer. 2017;3:293-303.
    >> Share

  3. HAQUE W, Verma V, Butler EB, Teh BS, et al
    Chemotherapy Versus Chemoradiation for Node-Positive Bladder Cancer: Practice Patterns and Outcomes from the National Cancer Data Base.
    Bladder Cancer. 2017;3:283-291.
    >> Share

  4. MALONEY I, Parker DC, Cookson MS, Patel S, et al
    Bladder Cancer Recovery Pathways: A Systematic Review.
    Bladder Cancer. 2017;3:269-281.
    >> Share

  5. MORAN GW, Li G, Robins DJ, Matulay JT, et al
    Systematic Review and Meta-Analysis on the Efficacy of Chemotherapy with Transurethral Resection of Bladder Tumors as Definitive Therapy for Muscle Invasive Bladder Cancer.
    Bladder Cancer. 2017;3:245-258.
    >> Share

  6. KOTI M, Xu AS, Ren KYM, Visram K, et al
    Tertiary Lymphoid Structures Associate with Tumour Stage in Urothelial Bladder Cancer.
    Bladder Cancer. 2017;3:259-267.
    >> Share

    Clin Genitourin Cancer

  7. ZAHOOR H, Elson P, Stephenson A, Haber GP, et al
    Patient Characteristics, Treatment Patterns and Prognostic Factors in Squamous Cell Bladder Cancer.
    Clin Genitourin Cancer. 2017 Oct 17. pii: S1558-7673(17)30311.
    >> Share

    Clin Transl Oncol

  8. BONET M, Bonfill T, Nunez M, De Verdonces L, et al
    Curative radiation therapy for very elderly bladder cancer patients with localized disease.
    Clin Transl Oncol. 2017 Nov 20. doi: 10.1007/s12094-017-1804.
    >> Share

    Eur Urol Focus

  9. DOMINGUEZ-ESCRIG JL, Peyronnet B, Seisen T, Bruins HM, et al
    Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer.
    Eur Urol Focus. 2017 Nov 17. pii: S2405-4569(17)30236.
    >> Share

    Front Oncol

  10. PRASANNA T, Craft P, Balasingam G, Haxhimolla H, et al
    Intravesical Gemcitabine versus Intravesical Bacillus Calmette-Guerin for the Treatment of Non-Muscle Invasive Bladder Cancer: An Evaluation of Efficacy and Toxicity.
    Front Oncol. 2017;7:260.
    >> Share

    Genes (Basel)

  11. GULIA C, Baldassarra S, Signore F, Rigon G, et al
    Role of Non-Coding RNAs in the Etiology of Bladder Cancer.
    Genes (Basel). 2017;8.
    >> Share

    Int J Mol Sci

  12. ECKE TH, Otto T
    Illumination of a Vision-How Arthur Rimbaud Will Give Us Motivation to Find New Input into Bladder Cancer Biomarker Research.
    Int J Mol Sci. 2017;18.
    >> Share

    J Cancer

  13. XIE H, Liao X, Chen Z, Fang Y, et al
    LncRNA MALAT1 Inhibits Apoptosis and Promotes Invasion by Antagonizing miR-125b in Bladder Cancer Cells.
    J Cancer. 2017;8:3803-3811.
    >> Share

  14. XU XL, Ye YL, Wu ZM, He QM, et al
    Overexpression of PTK6 predicts poor prognosis in bladder cancer patients.
    J Cancer. 2017;8:3464-3473.
    >> Share

  15. YANG X, Yuan W, Tao J, Li P, et al
    Identification of circular RNA signature in bladder cancer.
    J Cancer. 2017;8:3456-3463.
    >> Share

  16. PICHLER R, Fritz J, Heidegger I, Oberaigner W, et al
    Gender-related Outcome in Bladder Cancer Patients undergoing Radical Cystectomy.
    J Cancer. 2017;8:3567-3574.
    >> Share

    J Immunother Cancer

  17. AGGEN DH, Drake CG
    Biomarkers for immunotherapy in bladder cancer: a moving target.
    J Immunother Cancer. 2017;5:94.
    >> Share

    J Urol

  18. CASILLA-LENNON MM, Choi SK, Deal AM, Bensen JT, et al
    Financial Toxicity in Bladder Cancer Patients- Reasons for Delay in Care and Effect on Quality of Life.
    J Urol. 2017 Nov 16. pii: S0022-5347(17)77917-7. doi: 10.1016/j.juro.2017.
    >> Share

  19. KOUMPAN Y, Jaeger M, Mizubuti GB, Tanzola R, et al
    Spinal Anesthesia is Associated with Lower Recurrence Rates after Resection of Non-Muscle Invasive Bladder Cancer.
    J Urol. 2017 Nov 14. pii: S0022-5347(17)77909-8. doi: 10.1016/j.juro.2017.
    >> Share


  20. VIRANI NA, Davis C, McKernan P, Hauser P, et al
    Phosphatidylserine targeted single-walled carbon nanotubes for photothermal ablation of bladder cancer.
    Nanotechnology. 2017 Nov 21. doi: 10.1088/1361-6528.
    >> Share

    Neurourol Urodyn

  21. ISMAIL S, Karsenty G, Chartier-Kastler E, Cussenot O, et al
    Prevalence, management, and prognosis of bladder cancer in patients with neurogenic bladder: A systematic review.
    Neurourol Urodyn. 2017 Nov 23. doi: 10.1002/nau.23457.
    >> Share

    Oncol Lett

  22. GAN Y, He L, Yao K, Tan J, et al
    Knockdown of HMGN5 increases the chemosensitivity of human urothelial bladder cancer cells to cisplatin by targeting PI3K/Akt signaling.
    Oncol Lett. 2017;14:6463-6470.
    >> Share


  23. ANAN G, Hatakeyama S, Fujita N, Iwamura H, et al
    Trends in neoadjuvant chemotherapy use and oncological outcomes for muscle-invasive bladder cancer in Japan: a multicenter study.
    Oncotarget. 2017;8:86130-86142.
    >> Share

    Urol Oncol

  24. FERGUSON JE 3RD, Kamat AM
    It's all about the perspective: Removing bias when co-managing patients with high-grade T1 bladder cancer and localized prostate cancer-A competing risks analysis.
    Urol Oncol. 2017 Nov 17. pii: S1078-1439(17)30556.
    >> Share

  25. SMITH AB
    Recent developments in the management of bladder cancer: Introduction.
    Urol Oncol. 2017 Nov 17. pii: S1078-1439(17)30563.
    >> Share


  26. MORA VIDAL R, Regufe da Mota S, Hayden A, Markham H, et al
    EGFR Family Inhibition Identifies P38 MAPK as a Potential Therapeutic Target in Bladder Cancer.
    Urology. 2017 Nov 15. pii: S0090-4295(17)31184.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016